Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 03, 2022 07:30 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics

Rewrite Therapeutics’ proprietary and versatile DNA writing platform enables a range of novel genome editing strategiesAcquisition further expands Intellia’s industry-leading genome editing toolbox by...
January 06, 2022 07:30 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022

Advance clinical development of NTLA-2001, a potential single-dose therapy for transthyretin (ATTR) amyloidosis; on track to present additional data from Phase 1 study in Q1 2022Achieve preliminary...
January 05, 2022 16:01 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging...
January 05, 2022 07:30 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases

— Intellia grants Kyverna exclusive rights to its differentiated allogeneic cell engineering platform for the development of KYV-201, a next-generation CD19 CAR T-cell therapy to treat autoimmune...
December 20, 2021 07:30 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer

CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9...
December 13, 2021 07:30 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using...
November 22, 2021 07:30 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)

CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced today that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has...
November 05, 2021 07:30 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting

CAMBRIDGE, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using...
November 04, 2021 07:30 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

Initiated dosing of Cohort 4 in the ongoing Phase 1 study of NTLA-2001; data update from completed dose-escalation (Part 1) and initiation of dose-expansion (Part 2) expected in Q1 2022Accelerated...
October 28, 2021 07:30 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company Updates

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using...